Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients

Critical Care Medicine

Volumn 31, Issue 5, 2003, Pages 1347-1352

  Kanji, Salmaan ^a   McKinnon, Peggy S ^b   Barletta, Jeffrey F ^b   Kruse, James A ^c   Devlin, John W ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b DETROIT RECEIVING HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic; Area under the curve; Biological availability; Critical illness; Drug administration routes; Drug therapy; Enteral nutrition; Fluoroquinolone antiinfective agents; Gatifloxacin; Pharmacokinetics

Indexed keywords

GATIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; ENTERIC FEEDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTENSIVE CARE UNIT; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STOMACH TUBE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; APACHE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRITICAL ILLNESS; CROSS-OVER STUDIES; DRUG MONITORING; ENTERAL NUTRITION; FEMALE; FLUOROQUINOLONES; FOOD-DRUG INTERACTIONS; HUMANS; INFUSIONS, INTRAVENOUS; INTUBATION, GASTROINTESTINAL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0038582342     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000059317.75234.46     Document Type: Article

References (40)

1. Louis TJ: Intravenous to oral stepdown antibiotic therapy: Another cost-effective strategy in an era of shrinking health care dollars. Can J Infect Dis 1994; 5:45C-50C
2. Ramirez JA, Vargas S, Ritter GW, et al: Early switch from intravenous to oral antibiotics and early hospital discharge: A prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159:2449-2454
3. Laing RB, Mackenzie AR, Shaw H, et al: The effect of intravenous-to-oral switch guidelines on the use of parenteral antimicrobials in medical wards. J Antimicrob Chemother 1998; 42:107-111
4. Rifenburg RP, Paladino JA, Hanson SC, et al: Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. Am J Health Syst Pharm 1996; 53:2054-2062
5. Gould IM, Jappy B: Trends in hospital antimicrobial prescribing after 9 years of stewardship. J Antimicrob Chemother 2000; 45:913-917
6. Drew RH: Programs promoting timely sequential antimicrobial therapy: An American perspective. J Infect 1998; 37(Suppl 1):3-9
7. MacGregor RR, Graziani AL: Oral administration of antibiotics: A rational alternative to the parenteral route. Clin Infect Dis 1997; 24:457-467
8. Hamilton-Miller JM: Switch therapy: The theory and practice of early change from parenteral to non-parenteral antibiotic administration. Clin Microbiol Infect 1996; 2:12-19
9. Conley J: Intravenous to oral antibiotic step-down therapy: Improving the quality of care and reducing costs. Can J Infect Dis 1995; 5:62-72
10. Davey P, Nathwani D: Sequential antibiotic therapy: The right patient, the right time and the right outcome. J Infect 1998; 37(Suppl 1):37-44
11. Nathwani D, Tillotson G, Davey P: Sequential antimicrobial therapy: The role of quinolones. J Antimicrob Chemother 1997; 39:441-446
12. Lelekis M, Gould IM: Sequential antibiotic therapy for cost containment in the hospital setting: Why not? J Hosp Infect 2001; 48:249-257
13. Perry CM, Barman Balfour JA, Lamb HM: Gatifloxacin. Drugs 1999; 58:683-696
14. LaCreta FP, Kaul S, Kollia GD, et al: Interchangeability of 400 mg intravenous and oral gatifloxacin in healthy adults. Pharmacotherapy 2000; 20:59S-66S
15. Dasta JF, Armstrong DK: Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med 1988; 16:327-330
16. D'Espine M, Bellido F, Pechere JC, et al: Serum levels of ciprofloxacin after single oral doses in patients with septicemia. Eur J Clin Microbiol Infect Dis 1989; 8:1019-1023
17. Forrest A, Nix DE, Ballow CH, et al: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-1081
18. van Dalen R, Vree TB: Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med 1990; 16:S235-S238
19. Yuen GJ, Drusano GL, Plaisance K, et al: Ciprofloxacin pharmacokinetics in critically ill trauma patients. Am J Med 1989; 87:70S-75S
20. Bodenham A, Shelly MP, Park GR: The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet 1988; 14:347-373
21. Bush LM, Levison ME: Antibiotic selection and pharmacokinetics in the critically ill. Crit Care Clin 1988; 4:299-324
22. Olsen KM, Rebuck JA, Weidenbach T, et al: Pharmacokinetics of intravenous trovafloxacin in critically ill adults. Pharmacotherapy 2000; 20:400-404
23. Cohn SM, Sawyer MD, Burns GA, et al: Enteric absorption of ciprofloxacin during tube feeding in the critically ill. J Antimicrob Chemother 1996; 38:871-876
24. Mimoz O, Binter V, Jacolot A, et al: Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med 1998; 24:1047-1051
25. Rodman DP, Stevenson TL, Ray TR: Phenytoin malabsorption after jejunostomy tube delivery. Pharmacotherapy 1995; 15:801-805
26. Rosemurgy AS, Markowsky S, Goode SE, et al: Bioavailability of fluconazole in surgical intensive care unit patients: A study comparing routes of administration. J Trauma 1995; 39:445-447
27. Bass J, Miles MV, Tennison MB, et al: Effects of enteral tube feeding on the absorption and pharmacokinetic profile of carbamazepine suspension. Epilepsia 1989; 30:364-369
28. Healy DP, Brodbeck MC, Clendening CE: Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chernother 1996; 40:6-10
29. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
30. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41
31. Westlake WJ: Bioavailability and bioequivalence of pharmaceutical formulations. In: Biopharmaceutical Statistics for Drug Development. Peace KE (Ed). New York, Marcel Dekker, 1988, pp 329-352
32. Lober S, Ziege S, Rau M, et al: Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother 1999; 43:1067-1071
33. Kang SL, Rybak MJ, McGrath BJ, et al: Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother 1994; 38:2702-2709
34. Madaras-Kelly KJ, Ostergaard BE, Hovde LB, et al: Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996; 40:627-632
35. Lacy MK, Lu W, Xu X, et al: Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999; 43:672-677
36. Lister PD, Sanders CC: Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1999; 43:79-86
37. Craig WA: Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10
38. Blondeau JM: Gatifloxacin: A new fluoroquinolone. Expert Opin Investig Drugs 2000; 9:1877-1895
39. Fish DN, North DS: Gatifloxacin, an advanced 8-methoxy fluoroquinolone. Pharmacotherapy 2001; 21:35-59
40. Warren DK, Fraser VJ: Infection control measures to limit antimicrobial resistance. Crit Care Med 2001; 29:N128-N134